Cocrystal Pharma Inc
NASDAQ:COCP
Cocrystal Pharma Inc
Change in Working Capital
Cocrystal Pharma Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
Change in Working Capital
$303k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-19%
|
CAGR 10-Years
4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$8.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$1.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$7B
|
CAGR 3-Years
-94%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-90%
|
|
Cocrystal Pharma Inc
Glance View
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 13 full-time employees. The company went IPO on 2018-03-12. The firm focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The firm focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The firm uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. The company has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.
See Also
What is Cocrystal Pharma Inc's Change in Working Capital?
Change in Working Capital
303k
USD
Based on the financial report for Mar 31, 2025, Cocrystal Pharma Inc's Change in Working Capital amounts to 303k USD.
What is Cocrystal Pharma Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
4%
You don't have any saved screeners yet